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months. Methods: In PRIME, 1183 patients with previously untreated mCRC 
were randomised. Using data from an exploratory analysis conducted when 80% 
of patients had died, NNTs (Bender. Encyclopedia of Biostatistics, Second Edition; 
Volume 6, pp3752-61) were retrospectively calculated in patients with KRAS/NRAS 
WT (n= 505; exons 2-4 assessed) mCRC overall and in the ECOG performance score 
0/1 (n= 473) subgroup. ORR and PFS events were defined using RECIST. Results: 
In the overall KRAS/NRAS WT population, 59.3% vs 45.6% of patients receiving 
panitumumab+FOLFOX4 vs FOLFOX4 alone, respectively, achieved an OR; NNT(95% 
CI) in the ORR analysis was 7.3(4.5-19.9). In the ECOG 0/1 subgroup, 61.3% vs 46.4% 
of those receiving panitumumab+FOLFOX4 vs FOLFOX4 alone, respectively, had an 
OR; the NNT(95% CI) was 6.7(4.2-16.5). For the PFS overall population analysis, the 
HR(95% CI) was 0.74(0.62-0.90); HR(95% CI) for the ECOG 0/1 subgroup was 0.72(0.59-
0.88). NNTs(95% CI) in the overall population at 6 and 12 months were 12.8(8.3-34.1) 
and 9.2(5.7-25.9), respectively; corresponding values for the ECOG 0/1 subgroup were 
11.9(7.9-27.8) and 8.4(5.3-20.8). For the OS overall population analysis, the HR(95% 
CI) was 0.76(0.63-0.93); HR(95% CI) for the ECOG 0/1 subgroup was 0.74(0.60-0.90). 
NNTs(95% CI) in the overall population at 12 and 24 months were 16.8(10.4-57.1) and 
10.4(6.2-37.1), respectively; corresponding values for the ECOG 0/1 subgroup were 
16.0(10.3-44.1) and 9.4(5.9-27.2). ConClusions: In these analyses NNTs for PFS, 
OS and particularly ORR were low, reflecting the high therapeutic benefit of adding 
panitumumab to FOLFOX4 in patients with KRAS/NRAS WT mCRC. Limitation by 
ECOG score 0/1 further lowered NNTs for PFS and OS.
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objeCtives: T-DM1, an antibody-drug conjugate which combines the antitumor 
properties of trastuzumab (H) with the cytotoxic agent DM1, is approved for the 
treatment of patients with MBC previously treated with trastuzumab+taxane. We 
compared the clinical effectiveness of T-DM1 versus all available therapies used in 
the treatment of unresectable HER2-positive locally advanced breast cancer (LABC) 
or MBC. Methods: This systematic review (SR) and indirect treatment comparison 
(ITC) included all published data between January 1, 1998 and December 20, 2012. 
Studies were chosen in accordance with conventional methods for performing and 
reporting SRs and ITCs (i.e., Cochrane Handbook for SRs, PRISMA, ISPOR guidelines, 
and major HTA agencies). Eligible trials were controlled trials of treatments for 
unresectable HER2-positive LABC or MBC that had progressed after treatment with 
combination of trastuzumab+taxane in the adjuvant or MBC setting. Progression 
had to have occurred after the most recent treatment for LABC or MBC or within 6 
months after treatment for early-stage disease. Results: Seven RCTs and two non-
randomized controlled trials (n-RCTs) met the inclusion criteria. Of the seven RCTs, 
five had a common comparator, being eligible for the ITC. The other two RCTs and 
two n-RCTs did not have a common comparator and were thus not included in the 
ITC. T-DM1 was the only treatment to demonstrate statistically significantly longer 
overall survival (OS) and progression-free survival (PFS) when directly compared to 
capecitabine+lapatinib, and when indirectly compared to capecitabine+trastuzumab 
(PFS HR [95% CI]: 0.53 [0.32, 0.86], p= 0.01; OS HR [95% CI]: 0.56 [0.35, 0.91]; p= 0.01) 
and capecitabine monotherapy (PFS HR [95% CI]: 0.36 [0.25, 0.51]; p< 0.0001); OS (HR 
[95% CI]: 0.53 (0.39, 0.72); p= 0.0009). ConClusions: In this ITC, T-DM1 was associ-
ated with longer OS and PFS versus capecitabine+trastuzumab and capecitabine 
monotherapy in patients with HER2-positive LABC or MBC with disease progression 
after treatment with trastuzumab+taxane.
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objeCtives: To investigate the efficacy and safety of second-line chemotherapy in 
mCRC and to determine the feasibility of relative efficacy between treatments using 
indirect or mixed treatment comparisons. Methods: An SLR on randomized trials 
published from 1992–2012 was performed. EMBASE, PubMed, CENTRAL databases 
were consulted. Manual searches (including ASCO and ESMO abstracts) were also 
conducted. Eligible studies evaluated second-line clinical efficacy and safety end-
points in mCRC. Results: Twenty-seven trials with patients enrolled ranging from 
n= 33–1,226 were identified. Patients were markedly diverse in terms of ECOG, EGFR, 
or KRAS status, and prior treatment exposures: oxaliplatin (k= 9), irinotecan +/- 5-FU 
(k= 5), bevacizumab (k= 7), and 5-FU (k= 22). On-study treatments and comparators 
were also diverse: FOLFIRI alone (t= 6) or with panitumumab (t= 2) or aflibercept 
(t= 1); FOLFOX4 alone (t= 6) or with bevacizumab (t= 1); bevacizumab alone (t= 1) or 
with chemotherapy (t= 2); irinotecan alone (t= 19) or with FOLFOX4 (t= 2) or cetuxi-
mab (t= 1); and miscellaneous other regimens (t= 19). Study methodologies varied 
in analysis populations (ITT [k= 24] vs. per protocol or not reported [k= 3]), primary 
efficacy outcomes (OS, PFS, and/or tumor response, as variably measured), follow-up 
durations, and timing of outcomes measurements. Preliminary network diagrams to 
assess feasibility of meta-analyses for ITC revealed only a single study for each treat-
ment comparison of interest. Assumptions of comparability of apparently diverse 
patients, past and current treatment regimens, and comparator arms would be 
necessary to pool treatment groups for meta-analysis of treatment effectiveness 
across studies and hence, is not feasible. Given the lack of SOC treatments used in 
many trials, introducing such assumptions will compromise the evidence-based 
criteria for quantitative clinical data syntheses for indirect or mixed treatment 
Fixed and random effects models were explored with results reported for the best 
fitting model. Hazard ratio (HR) was chosen as the summary statistic. Results: The 
network of 6 RCTs formed a linear series of “steps”, which facilitated comparison of 
all chemotherapy regimens of interest. The fixed effects model was the best-fitting 
model. There was reasonable agreement between the number of unconstrained 
data points, residual deviance and pair-wise results, suggesting a coherent network. 
Using bevacizumab/gemcitabine/carboplatin as the baseline, the results for PFS 
for the other chemotherapy regimens were: platinum monotherapy (HR 2.92, 95% 
Credible Interval [CrI]: 2.10 to 3.96), gemcitabine/carboplatin (HR 2.09, 95% CrI: 1.65 
to 2.60), paclitaxel/carboplatin (HR 2.16, 95% CrI: 1.50 to 3.01), PLDH/carboplatin (HR 
1.77, 95% CrI: 1.20 to 2.51); where a HR> 1 favours bevacizumab/gemcitabine/carbo-
platin and a HR< 1 favours the comparator. ConClusions: This research suggests 
bevacizumab in combination with gemcitabine/carboplatin may offer significantly 
longer PFS compared with other chemotherapy options available in the UK.
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objeCtives: Brentuximab vedotin (ADCETRIS®), a CD30-targeted antibody-drug 
conjugate, has conditional approval in Europe for the treatment of adult patients 
with RR sALCL. This systematic review summarized the efficacy of other treatments 
for RR ALCL, for comparison with brentuximab vedotin. Methods: A systematic 
literature review identified studies published between 1993 and February 2013 report-
ing efficacy of treatments in adult patients with RR ALCL, or more generally with RR 
peripheral T-cell lymphoma (PTCL) including ≥ 1 ALCL patient. Five databases were 
included: EMBASE, MEDLINE, and the WHO ICTRP; reviews published since 2011 were 
also searched manually for additional studies. English publications reporting com-
plete remission/response (CR) rate and/or 2-year overall survival (OS) in RR ALCL/
PTCL populations were included. Publications of principal treatment with bone mar-
row transplantation or radiotherapy were excluded. CR rates and 2-year OS, from 
the identified studies and from the brentuximab vedotin single-arm phase 2 trial 
in sALCL (SG035-0004), were summarized. Results: Of 1653 publications screened, 
12 studies were eligible for inclusion; all were phase 1 or 2 or unspecified prospec-
tive non-randomized studies. For these studies, the CR rates were 0–28% in RR PTCL 
patients (n= 4–130 PTCL; median age 36–69 years; n= 1–41 ALCL), and for the 6 studies 
that also reported CR outcomes in the subset of RR ALCL patients (n= 13–130 PTCL; 
median age 47–69 years; n= 2–41 ALCL), the CR rates were 0–33% in RR ALCL patients. 
For RR ALCL patients treated with brentuximab vedotin in SG035-0004 (n= 58 sALCL; 
median age 52 years) the CR rate was 59%. The 2-year OS ranged from 7–33% in the 
5 identified studies that reported OS, compared with 63% with brentuximab vedotin 
in SG035-0004. ConClusions: The CR rate and 2-year OS for brentuximab vedotin 
in RR sALCL appear to exceed that of other therapies in RR ALCL/PTCL.
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objeCtives: Although gastric cancer has decreased in the last three decades, it is 
still the second leading cause of cancer death worldwide. In Asian countries, the 
burden of gastric cancer has remained, and screening is still expected to prevent 
gastric cancer death. In order to evaluate reduction of mortality from gastric cancer 
by endoscopic screening, a community-based, case-control study was conducted in 
Japan. Methods: Case subjects were defined as persons who had died of gastric 
cancer between 2003 and 2006 in four cities, Tottori Prefecture, and between 2006 
and 2010 in Niigata City, Japan. Up to six control subjects were matched by sex, birth 
year (±3 years), and residence of each corresponding case from population lists in the 
study areas. Controls were required to be disease-free at the time when the case was 
diagnosed gastric cancer. The odds ratios were calculated for those who had ever par-
ticipated in endoscopic screening or radiographic screening before the reference date 
when the case was diagnosed gastric cancer, compared with persons who had never 
participated in any screening. Conditional logistic-regression models for matched sets 
were used to estimate the odds ratios and 95% confidence intervals. Results: There 
were 288 males and 122 females for case subjects, with 2,292 matched control subjects. 
Compared with those who had never been screened before the date of diagnosis of 
gastric cancer in cases, the odds ratios within 48 months from the diagnosis date 
were 0.703 (95% confidence interval :0.497-0.996) for endoscopic screening and 0.860 
(95% confidence interval :0.631-1.171) for radiographic screening. ConClusions: The 
result suggests a 30% reduction from gastric cancer mortality by endoscopic screening 
compared to no screening within 48 months before the diagnosis date of gastric cancer.
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objeCtives: To calculate NNTs for panitumumab+FOLFOX4 vs FOLFOX4 alone 
(PRIME study) to achieve one objective response (OR rate [ORR] analysis) or pre-
vent one disease progression (PFS analysis) or death (OS analysis) at 6/12 or 12/24 
